Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024
Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules. Vacc...
Gespeichert in:
| Veröffentlicht in: | Expert review of vaccines Jg. 23; H. 1; S. 887 - 910 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Taylor & Francis Group
31.12.2024
|
| Schlagworte: | |
| ISSN: | 1476-0584, 1744-8395, 1744-8395 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules.
Vaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies.
Current recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, that are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients. |
|---|---|
| AbstractList | Introduction Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules.Areas covered Vaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies.Expert opinion Current recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, which are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing ‘vaccination’ by ‘immunization’ schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients. Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules. Vaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies. Current recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, that are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients. Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules.INTRODUCTIONMonoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules.Vaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies.AREAS COVEREDVaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies.Current recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, which are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients.EXPERT OPINIONCurrent recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, which are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients. |
| Author | Rivera-Izquierdo, Mario Morales-Portillo, Arturo Fernández-Martínez, Nicolás Francisco Schoenenberger-Arnaiz, Joan Antoni Guerrero-Fernández de Alba, Inmaculada Barranco-Quintana, José Luis Valero-Ubierna, Carmen |
| Author_xml | – sequence: 1 givenname: Mario orcidid: 0000-0001-6159-6037 surname: Rivera-Izquierdo fullname: Rivera-Izquierdo, Mario – sequence: 2 givenname: Arturo surname: Morales-Portillo fullname: Morales-Portillo, Arturo – sequence: 3 givenname: Inmaculada surname: Guerrero-Fernández de Alba fullname: Guerrero-Fernández de Alba, Inmaculada – sequence: 4 givenname: Nicolás Francisco orcidid: 0000-0001-8257-4304 surname: Fernández-Martínez fullname: Fernández-Martínez, Nicolás Francisco – sequence: 5 givenname: Joan Antoni surname: Schoenenberger-Arnaiz fullname: Schoenenberger-Arnaiz, Joan Antoni – sequence: 6 givenname: José Luis orcidid: 0000-0002-6925-8363 surname: Barranco-Quintana fullname: Barranco-Quintana, José Luis – sequence: 7 givenname: Carmen surname: Valero-Ubierna fullname: Valero-Ubierna, Carmen |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39258843$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UsluFDEQbaEgssAngHzkMsFrtxtOURQgKIgLcLW8VM846rYb250ov8RX4tk4cOBil6ree7WeNychBmia1wRfEizxO8K7FgvJLymm9eGYSNY_a85Ix_mqmuKk2hWz2oJOm_Oc7zFmvBfdi-aU9VRIydlZ8_unttYHXXwMKJekC6w9ZDTEhObqhVAyWoKDhKYYoh1j0CPSoXgT3VM1HIplU6PGxzGuva3RkkCXact8XwFomV1VdcjGaU6wgZD9A6AEDx4ekdG5hmrum69XSC9lE5PPu2oyKhF90WHR6Qltm3zZPB_0mOHV4b9ofny8-X79eXX37dPt9dXdynJKy2qgMJC-w7w1BneGEymYBCEkcZh2mlswTLLWEIMdHTqs-xbzQXadwQT3TLOL5nav66K-V3PyU61ARe3VzhHTWulUvB1BCWsxpw645R0fuNBMcs2MFrKlLQZXtd7uteYUfy2Qi5p8tjCOOkBcsmIEUymJELxC3xygi5nA_U183FUFfNgDbIo5JxiU9WU3qro2PyqC1fYy1PEy1HZo6nAZlS3-YR8T_J_3B73YvQw |
| CitedBy_id | crossref_primary_10_1016_j_jinf_2025_106538 |
| Cites_doi | 10.1016/j.tmaid.2017.12.004 10.1056/NEJMoa2207566 10.1093/infdis/jiw606 10.1002/ibd.21800 10.1016/j.ekir.2021.03.876 10.1093/cid/cit816 10.14745/ccdr.v49i23a08 10.1097/RHU.0000000000000877 10.1007/s00415-021-10744-x 10.1016/j.vaccine.2018.07.039 10.1128/CMR.00035-19 10.3390/vaccines11111680 10.1016/j.vaccine.2019.03.016 10.2807/1560-7917.ES.2023.28.49.2300606 10.1007/s13311-022-01224-9 10.1016/j.jns.2014.03.035 10.1177/1078155219837342 10.3389/fimmu.2022.978203 10.1002/lt.20674 10.3109/14397595.2013.843743 10.4103/0256-4947.87091 10.1080/14740338.2021.1946513 10.7224/1537-2073.2016-026 10.1093/infdis/jis487 10.1086/587063 10.1111/ajt.12122 10.1136/annrheumdis-2013-204427 10.3899/jrheum.111587 10.1016/j.vaccine.2020.09.004 10.1016/j.msard.2022.104486 10.1016/S0264-410X(97)00254-5 10.1016/j.vaccine.2016.10.055 10.4254/wjh.v9.i13.613 10.1016/j.eclinm.2023.101965 10.1002/cncr.31909 10.1038/s41467-023-39292-w 10.1002/art.39480 10.1080/21645515.2023.2278362 10.1080/21645515.2018.1445446 10.1016/j.nrl.2019.11.003 10.3899/jrheum.161407 10.1080/13696998.2023.2242169 10.1056/NEJMoa2116620 10.1016/j.coph.2012.08.001 10.1080/21645515.2016.1174354 10.15585/mmwr.mm6903a5 10.1016/j.msard.2019.04.004 10.1016/j.medcli.2019.02.003 10.1002/prp2.535 10.1056/NEJMoa1601277 10.1007/s10875-012-9813-x 10.1002/acr.22246 10.1080/14760584.2017.1338568 10.1007/s40120-023-00448-x 10.1111/j.1600-6143.2007.01982.x 10.1016/j.vaccine.2023.12.075 10.1093/cid/ciad349 10.1016/j.jaut.2017.03.011 10.1016/j.vaccine.2018.01.061 10.1016/j.cmi.2018.02.003 10.1021/jm401490p 10.1590/s0004-2803.201900000-77 10.2217/fmb-2018-0026 10.1080/21505594.2022.2146380 10.3390/vaccines8030385 10.1016/j.jaad.2013.06.046 10.1093/cid/civ144 10.3899/jrheum.130945 10.1371/journal.pone.0147856 10.1001/jama.2019.9053 10.1093/ofid/ofy174 10.1177/0961203317695465 10.14745/ccdr.v43i06a04 10.1016/S1473-3099(21)00403-5 10.1136/gutjnl-2014-307127 10.1016/j.ijid.2023.06.021 10.1007/s00393-020-00891-3 10.1093/infdis/jix178 10.1001/jamanetworkopen.2022.48664 10.1136/rmdopen-2017-000484 10.1080/21645515.2023.2191577 10.1002/art.25033 10.3389/fimmu.2019.01400 10.1586/14760584.2015.1051470 10.1007/s13238-010-0052-8 10.1002/art.21386 10.1080/14760584.2020.1800462 10.1016/j.vaccine.2022.12.009 10.1080/14760584.2018.1484286 10.4414/smw.2015.14159 10.1177/13524585221151124 10.1080/03007995.2017.1329140 10.1002/art.22504 10.1080/21645515.2018.1538618 10.1016/j.anai.2018.03.017 10.4254/wjh.v7.i24.2503 10.7861/clinmedicine.17-3-220 10.1093/cid/ciw855 10.1038/bmt.2017.24 10.3109/0284186X.2014.914243 10.1016/j.clim.2022.109144 10.1080/14760584.2023.2273892 10.1080/14760584.2017.1333906 10.1007/s40265-022-01733-z |
| ContentType | Journal Article |
| DBID | AAYXX CITATION NPM 7X8 DOA |
| DOI | 10.1080/14760584.2024.2401839 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1744-8395 |
| EndPage | 910 |
| ExternalDocumentID | oai_doaj_org_article_5cc042de4c474f45a384a3ba586260ed 39258843 10_1080_14760584_2024_2401839 |
| Genre | Journal Article Review |
| GroupedDBID | --- 0YH 29G 4.4 53G 5GY AAYXX ABEIZ ABLKL ABXYU ACGFS ADCVX AECIN AENEX AEOZL AESAV AFRVT AGDLA AHMBA AIJEM AIYSM AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU AQTUD BLEHA CCCUG CITATION CS3 DU5 EBS F5P GROUPED_DOAJ H13 HZ~ IAO IHR KYCEM LJTGL M4Z MV1 O9- P2P SJN TCNNB TDBHL TFL TFW TUROJ 0BK ALIPV NPM RFE 7X8 |
| ID | FETCH-LOGICAL-c422t-f2ef197046bb07b418538e5581d027a4ceb3836b1b0d2f70a9604f877b01093a3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 2 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001319241700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1476-0584 1744-8395 |
| IngestDate | Mon Oct 13 19:20:45 EDT 2025 Thu Sep 04 17:30:45 EDT 2025 Wed Feb 19 02:08:22 EST 2025 Sat Nov 29 07:21:24 EST 2025 Tue Nov 18 21:46:45 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | vaccine biologics mabs immunosuppression vaccine schedule nirsevimab Biologic therapy |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c422t-f2ef197046bb07b418538e5581d027a4ceb3836b1b0d2f70a9604f877b01093a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-6159-6037 0000-0001-8257-4304 0000-0002-6925-8363 |
| OpenAccessLink | https://doaj.org/article/5cc042de4c474f45a384a3ba586260ed |
| PMID | 39258843 |
| PQID | 3102881554 |
| PQPubID | 23479 |
| PageCount | 24 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5cc042de4c474f45a384a3ba586260ed proquest_miscellaneous_3102881554 pubmed_primary_39258843 crossref_citationtrail_10_1080_14760584_2024_2401839 crossref_primary_10_1080_14760584_2024_2401839 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-31 |
| PublicationDateYYYYMMDD | 2024-12-31 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Expert review of vaccines |
| PublicationTitleAlternate | Expert Rev Vaccines |
| PublicationYear | 2024 |
| Publisher | Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis Group |
| References | Scheen AJ (e_1_3_7_80_1) 2022; 77 e_1_3_7_41_1 e_1_3_7_60_1 e_1_3_7_83_1 e_1_3_7_45_1 e_1_3_7_64_1 e_1_3_7_87_1 e_1_3_7_22_1 e_1_3_7_49_1 e_1_3_7_26_1 e_1_3_7_68_1 e_1_3_7_122_1 e_1_3_7_103_1 e_1_3_7_107_1 e_1_3_7_126_1 e_1_3_7_91_1 e_1_3_7_30_1 e_1_3_7_72_1 e_1_3_7_99_1 e_1_3_7_11_1 e_1_3_7_34_1 e_1_3_7_53_1 e_1_3_7_76_1 e_1_3_7_95_1 e_1_3_7_15_1 e_1_3_7_38_1 e_1_3_7_57_1 e_1_3_7_111_1 e_1_3_7_19_1 e_1_3_7_115_1 e_1_3_7_4_1 e_1_3_7_119_1 e_1_3_7_8_1 e_1_3_7_84_1 e_1_3_7_61_1 e_1_3_7_88_1 e_1_3_7_23_1 e_1_3_7_42_1 e_1_3_7_65_1 e_1_3_7_27_1 e_1_3_7_46_1 e_1_3_7_69_1 e_1_3_7_121_1 e_1_3_7_102_1 e_1_3_7_106_1 e_1_3_7_125_1 e_1_3_7_92_1 e_1_3_7_73_1 e_1_3_7_50_1 e_1_3_7_31_1 e_1_3_7_77_1 e_1_3_7_12_1 e_1_3_7_96_1 e_1_3_7_35_1 Public Health England (e_1_3_7_56_1) 2016 e_1_3_7_16_1 e_1_3_7_58_1 e_1_3_7_39_1 e_1_3_7_110_1 e_1_3_7_114_1 e_1_3_7_5_1 e_1_3_7_118_1 e_1_3_7_9_1 e_1_3_7_109_1 e_1_3_7_81_1 e_1_3_7_62_1 e_1_3_7_85_1 e_1_3_7_66_1 e_1_3_7_89_1 e_1_3_7_20_1 e_1_3_7_43_1 e_1_3_7_24_1 e_1_3_7_47_1 e_1_3_7_28_1 e_1_3_7_120_1 e_1_3_7_101_1 e_1_3_7_124_1 e_1_3_7_105_1 e_1_3_7_70_1 e_1_3_7_51_1 e_1_3_7_74_1 e_1_3_7_97_1 e_1_3_7_32_1 e_1_3_7_55_1 e_1_3_7_78_1 e_1_3_7_93_1 Brodmerkel C (e_1_3_7_52_1) 2013; 12 e_1_3_7_13_1 e_1_3_7_36_1 e_1_3_7_59_1 e_1_3_7_17_1 e_1_3_7_113_1 e_1_3_7_6_1 e_1_3_7_117_1 e_1_3_7_40_1 e_1_3_7_63_1 e_1_3_7_82_1 e_1_3_7_21_1 e_1_3_7_44_1 e_1_3_7_67_1 e_1_3_7_86_1 e_1_3_7_25_1 e_1_3_7_48_1 e_1_3_7_29_1 e_1_3_7_100_1 e_1_3_7_104_1 e_1_3_7_127_1 e_1_3_7_108_1 e_1_3_7_123_1 e_1_3_7_90_1 e_1_3_7_98_1 e_1_3_7_71_1 e_1_3_7_10_1 American Academy of Pediatrics (e_1_3_7_54_1) 2015 e_1_3_7_94_1 e_1_3_7_33_1 e_1_3_7_75_1 e_1_3_7_14_1 e_1_3_7_37_1 e_1_3_7_79_1 e_1_3_7_18_1 e_1_3_7_3_1 e_1_3_7_112_1 e_1_3_7_7_1 e_1_3_7_116_1 |
| References_xml | – ident: e_1_3_7_103_1 doi: 10.1016/j.tmaid.2017.12.004 – ident: e_1_3_7_25_1 doi: 10.1056/NEJMoa2207566 – ident: e_1_3_7_98_1 doi: 10.1093/infdis/jiw606 – ident: e_1_3_7_24_1 – ident: e_1_3_7_75_1 doi: 10.1002/ibd.21800 – ident: e_1_3_7_10_1 doi: 10.1016/j.ekir.2021.03.876 – ident: e_1_3_7_31_1 doi: 10.1093/cid/cit816 – ident: e_1_3_7_79_1 doi: 10.14745/ccdr.v49i23a08 – ident: e_1_3_7_89_1 doi: 10.1097/RHU.0000000000000877 – volume-title: Immunisation against infectious diseases: immunisation of individuals with underlying medical conditions year: 2016 ident: e_1_3_7_56_1 – ident: e_1_3_7_20_1 doi: 10.1007/s00415-021-10744-x – ident: e_1_3_7_76_1 doi: 10.1016/j.vaccine.2018.07.039 – ident: e_1_3_7_19_1 doi: 10.1128/CMR.00035-19 – ident: e_1_3_7_37_1 doi: 10.3390/vaccines11111680 – ident: e_1_3_7_122_1 doi: 10.1016/j.vaccine.2019.03.016 – ident: e_1_3_7_27_1 doi: 10.2807/1560-7917.ES.2023.28.49.2300606 – ident: e_1_3_7_61_1 doi: 10.1007/s13311-022-01224-9 – ident: e_1_3_7_41_1 doi: 10.1016/j.jns.2014.03.035 – ident: e_1_3_7_102_1 doi: 10.1177/1078155219837342 – ident: e_1_3_7_116_1 doi: 10.3389/fimmu.2022.978203 – ident: e_1_3_7_95_1 doi: 10.1002/lt.20674 – ident: e_1_3_7_50_1 doi: 10.3109/14397595.2013.843743 – ident: e_1_3_7_90_1 doi: 10.4103/0256-4947.87091 – ident: e_1_3_7_18_1 doi: 10.1080/14740338.2021.1946513 – ident: e_1_3_7_40_1 doi: 10.7224/1537-2073.2016-026 – ident: e_1_3_7_70_1 doi: 10.1093/infdis/jis487 – ident: e_1_3_7_100_1 doi: 10.1086/587063 – ident: e_1_3_7_7_1 – ident: e_1_3_7_121_1 doi: 10.1111/ajt.12122 – ident: e_1_3_7_49_1 doi: 10.1136/annrheumdis-2013-204427 – ident: e_1_3_7_38_1 doi: 10.3899/jrheum.111587 – ident: e_1_3_7_69_1 doi: 10.1016/j.vaccine.2020.09.004 – ident: e_1_3_7_9_1 doi: 10.1016/j.msard.2022.104486 – ident: e_1_3_7_88_1 doi: 10.1016/S0264-410X(97)00254-5 – ident: e_1_3_7_112_1 doi: 10.1016/j.vaccine.2016.10.055 – ident: e_1_3_7_55_1 – ident: e_1_3_7_101_1 doi: 10.4254/wjh.v9.i13.613 – ident: e_1_3_7_32_1 doi: 10.1016/j.eclinm.2023.101965 – ident: e_1_3_7_111_1 doi: 10.1002/cncr.31909 – ident: e_1_3_7_58_1 doi: 10.1093/cid/cit816 – ident: e_1_3_7_13_1 doi: 10.1038/s41467-023-39292-w – ident: e_1_3_7_106_1 doi: 10.1002/art.39480 – ident: e_1_3_7_115_1 doi: 10.1080/21645515.2023.2278362 – ident: e_1_3_7_64_1 doi: 10.1080/21645515.2018.1445446 – ident: e_1_3_7_108_1 doi: 10.1016/j.nrl.2019.11.003 – ident: e_1_3_7_30_1 – ident: e_1_3_7_36_1 doi: 10.3899/jrheum.161407 – ident: e_1_3_7_22_1 doi: 10.1080/13696998.2023.2242169 – ident: e_1_3_7_23_1 doi: 10.1056/NEJMoa2116620 – ident: e_1_3_7_5_1 doi: 10.1016/j.coph.2012.08.001 – ident: e_1_3_7_87_1 doi: 10.1080/21645515.2016.1174354 – ident: e_1_3_7_118_1 doi: 10.15585/mmwr.mm6903a5 – ident: e_1_3_7_62_1 doi: 10.1016/j.msard.2019.04.004 – ident: e_1_3_7_63_1 doi: 10.1016/j.medcli.2019.02.003 – ident: e_1_3_7_3_1 doi: 10.1002/prp2.535 – ident: e_1_3_7_43_1 doi: 10.1056/NEJMoa1601277 – ident: e_1_3_7_44_1 doi: 10.1007/s10875-012-9813-x – ident: e_1_3_7_74_1 doi: 10.1002/acr.22246 – ident: e_1_3_7_91_1 doi: 10.1080/14760584.2017.1338568 – ident: e_1_3_7_59_1 – ident: e_1_3_7_42_1 doi: 10.1007/s40120-023-00448-x – ident: e_1_3_7_66_1 doi: 10.1111/j.1600-6143.2007.01982.x – ident: e_1_3_7_84_1 doi: 10.1016/j.vaccine.2023.12.075 – ident: e_1_3_7_83_1 doi: 10.1093/cid/ciad349 – ident: e_1_3_7_33_1 doi: 10.1016/j.jaut.2017.03.011 – ident: e_1_3_7_34_1 doi: 10.1016/j.vaccine.2018.01.061 – volume: 77 start-page: 678 issue: 11 year: 2022 ident: e_1_3_7_80_1 article-title: Apexxnar®, vaccin anti-pneumococcique conjugué avec 20 sérotypes [Apexxnar®, 20-valent pneumococcal conjugate vaccine] publication-title: Rev Med Liege – ident: e_1_3_7_21_1 doi: 10.1016/j.cmi.2018.02.003 – ident: e_1_3_7_113_1 doi: 10.1021/jm401490p – ident: e_1_3_7_94_1 doi: 10.1590/s0004-2803.201900000-77 – ident: e_1_3_7_124_1 doi: 10.2217/fmb-2018-0026 – ident: e_1_3_7_11_1 doi: 10.1080/21505594.2022.2146380 – ident: e_1_3_7_119_1 doi: 10.3390/vaccines8030385 – ident: e_1_3_7_105_1 doi: 10.1016/j.jaad.2013.06.046 – ident: e_1_3_7_123_1 doi: 10.1093/cid/civ144 – ident: e_1_3_7_15_1 – volume: 12 start-page: 1122 issue: 10 year: 2013 ident: e_1_3_7_52_1 article-title: Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use publication-title: J Drugs Dermatol – ident: e_1_3_7_29_1 – ident: e_1_3_7_39_1 doi: 10.3899/jrheum.130945 – ident: e_1_3_7_60_1 doi: 10.1371/journal.pone.0147856 – ident: e_1_3_7_110_1 doi: 10.1001/jama.2019.9053 – ident: e_1_3_7_117_1 – ident: e_1_3_7_99_1 doi: 10.1093/ofid/ofy174 – ident: e_1_3_7_114_1 – start-page: 74 volume-title: Red Book: 2015 Report of the Committee on Infectious Diseases year: 2015 ident: e_1_3_7_54_1 – ident: e_1_3_7_14_1 – ident: e_1_3_7_77_1 doi: 10.1177/0961203317695465 – ident: e_1_3_7_107_1 doi: 10.14745/ccdr.v43i06a04 – ident: e_1_3_7_126_1 doi: 10.1016/S1473-3099(21)00403-5 – ident: e_1_3_7_53_1 doi: 10.1136/gutjnl-2014-307127 – ident: e_1_3_7_12_1 doi: 10.1016/j.ijid.2023.06.021 – ident: e_1_3_7_35_1 doi: 10.1007/s00393-020-00891-3 – ident: e_1_3_7_82_1 – ident: e_1_3_7_97_1 doi: 10.1093/infdis/jix178 – ident: e_1_3_7_28_1 – ident: e_1_3_7_47_1 doi: 10.1001/jamanetworkopen.2022.48664 – ident: e_1_3_7_73_1 doi: 10.1136/rmdopen-2017-000484 – ident: e_1_3_7_85_1 doi: 10.1080/21645515.2023.2191577 – ident: e_1_3_7_45_1 doi: 10.1002/art.25033 – ident: e_1_3_7_71_1 doi: 10.3389/fimmu.2019.01400 – ident: e_1_3_7_104_1 – ident: e_1_3_7_57_1 – ident: e_1_3_7_109_1 doi: 10.1586/14760584.2015.1051470 – ident: e_1_3_7_6_1 doi: 10.1007/s13238-010-0052-8 – ident: e_1_3_7_16_1 doi: 10.1002/art.21386 – ident: e_1_3_7_8_1 doi: 10.1080/14760584.2020.1800462 – ident: e_1_3_7_93_1 doi: 10.1016/j.vaccine.2022.12.009 – ident: e_1_3_7_86_1 doi: 10.1080/14760584.2018.1484286 – ident: e_1_3_7_127_1 doi: 10.4414/smw.2015.14159 – ident: e_1_3_7_26_1 – ident: e_1_3_7_51_1 doi: 10.1177/13524585221151124 – ident: e_1_3_7_68_1 doi: 10.1080/03007995.2017.1329140 – ident: e_1_3_7_17_1 doi: 10.1002/art.22504 – ident: e_1_3_7_72_1 doi: 10.1080/21645515.2018.1538618 – ident: e_1_3_7_92_1 doi: 10.1016/j.anai.2018.03.017 – ident: e_1_3_7_96_1 doi: 10.4254/wjh.v7.i24.2503 – ident: e_1_3_7_4_1 doi: 10.7861/clinmedicine.17-3-220 – ident: e_1_3_7_67_1 doi: 10.1093/cid/ciw855 – ident: e_1_3_7_120_1 – ident: e_1_3_7_65_1 doi: 10.1038/bmt.2017.24 – ident: e_1_3_7_46_1 doi: 10.3109/0284186X.2014.914243 – ident: e_1_3_7_48_1 doi: 10.1016/j.clim.2022.109144 – ident: e_1_3_7_81_1 doi: 10.1080/14760584.2023.2273892 – ident: e_1_3_7_125_1 doi: 10.1080/14760584.2017.1333906 – ident: e_1_3_7_78_1 doi: 10.1007/s40265-022-01733-z |
| SSID | ssj0034957 |
| Score | 2.4154813 |
| SecondaryResourceType | review_article |
| Snippet | Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly... Introduction Monoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their... |
| SourceID | doaj proquest pubmed crossref |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source |
| StartPage | 887 |
| SubjectTerms | Biologic therapy biologics immunosuppression mAbs nirsevimab vaccine |
| Title | Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorisations to January 2024 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39258843 https://www.proquest.com/docview/3102881554 https://doaj.org/article/5cc042de4c474f45a384a3ba586260ed |
| Volume | 23 |
| WOSCitedRecordID | wos001319241700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1744-8395 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0034957 issn: 1476-0584 databaseCode: DOA dateStart: 20230101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 1744-8395 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0034957 issn: 1476-0584 databaseCode: TFW dateStart: 20020601 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 1744-8395 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0034957 issn: 1476-0584 databaseCode: 0YH dateStart: 20231201 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtaKGX0vSVTZswhV7dyJa80uaWliyltKGHtN2b0ZMsBDvY3sL-pfzKzFj2kkvJpRdjhB-yZmx9nzzzDWMfTW7nsszRAtpqJChRZYYLn0nppYk2cmEHEdfv6uJCr1aLn_dKfVFMWJIHTgN3UjqHfuWDdFLJKEsjtDTCmnKA4sHT15erxUSm0jdYIOwfyqpIhXwZ59gpd0fzE2qjJuSGBW6QX2iqFH5vVhrE-_-NOIeZZ_mCPR8hI5ylru6zR6F-yZ6mIpLbV-z2t3FunRb1oOsn6QdANAqjamoHlCrWArpc464JewMO6No2fos7HoYsLEh6TGQ02IWfd6d4AGxuaF3AA8Wft-EqxbxDynoBmgfxEjWc_zgDs-mvmnYKEYK-gW-mRi_cAo3Da_ZreX755Ws2VmDInCyKPotFiPlCIYe2litLQjdCh7JEkIt01kiHVFyLuc0t90VU3JDUS9RKWfrjJox4w_bqpg4HDMq5st5IH0wpkPIsjNMB_UFxF9GqOZ8xOVmgcqM8OVXJuK7yUcV0MlxFHa5Gw83Yp91pN0mf46ETPpN5dweTvPbQgE5XjU5XPeR0M_Zhco4KX0f6x2Lq0Gy6ShBg0wTSZuxt8prdrRCKUlqwOPwfXXjHntFjJc3J92yvbzfhiD1xf_t11x6zx2qlj4d3AreXyz93sk4McQ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vaccination+strategies+for+patients+under+monoclonal+antibody+and+other+biological+treatments%3A+an+updated+comprehensive+review+based+on+EMA+authorisations+to+January+2024&rft.jtitle=Expert+review+of+vaccines&rft.au=Mario+Rivera-Izquierdo&rft.au=Arturo+Morales-Portillo&rft.au=Inmaculada+Guerrero-Fern%C3%A1ndez+de+Alba&rft.au=Nicol%C3%A1s+Francisco+Fern%C3%A1ndez-Mart%C3%ADnez&rft.date=2024-12-31&rft.pub=Taylor+%26+Francis+Group&rft.issn=1476-0584&rft.eissn=1744-8395&rft.volume=23&rft.issue=1&rft.spage=887&rft.epage=910&rft_id=info:doi/10.1080%2F14760584.2024.2401839&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5cc042de4c474f45a384a3ba586260ed |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-0584&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-0584&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-0584&client=summon |